Summary: Comparison of three standard neoadjuvant chemotherapy regimens based on pathological tumor response in breast cancer patients.

Summary: Stage Ⅳ HER2-Positive Breast Cancer That Showed Complete Response for Over One Year after Discontinuation of Anti-HER2 Therapy-A Case Report.

Summary: The Efficacy of Combined Use of Pertuzumab and Trastuzumab-Based Neoadjuvant Chemotherapy for HER2 Positive Breast Cancer.

Summary: Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.

Summary: Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.

Summary: Clinical observation of palbociclib combined with endocrine therapy in hormone receptor positive and HER2 negative advanced breast cancer.

Summary: Observational real world data with palbociclib associated to hormone therapy for advanced breast carcinoma.

Summary: Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.

Summary: T-DM1 Increases the Risk of SRS-Induced Radiation Necrosis in Her2+ Breast Cancer.

Summary: Ten Fraction Adjuvant Hypofractionated Radiotherapy in Node Positive Breast Cancer: 3 Year-Follow-Up of a Phase II Toxicity Study.

Summary: Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer.

Summary: De-Escalation of Radiation Therapy in Patients with cT1-T2 (< 3 cm) N0 HER2+ Breast Cancer Treated With Neoadjuvant Systemic Therapy With Pathologic Complete Response at the Time of Breast Conserving Surgery.